Back

Abingworth raises $582 million for new Clinical Co-Development Fund – Over $1 billion raised in 2021 for two funds

  • Written By: Asante Capital

Asante Capital are pleased to announce the final closing of Abingworth’s new Clinical Co-Development Fund at $582 million. Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350 million and closing at its hard cap. Alongside the recent $465 million Abingworth Bioventures (ABV 8) flagship fund, Abingworth has raised over $1 billion to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.

Asante Capital Group acted as global placement advisor for the fundraise.

Please see full Press Release here.

To read more on the Times click here.

Asante Capital congratulates its partner Maguar Capital on the close of a more than €235 million continuation fund transaction for HRworks

We are delighted to share that Maguar Capital Capital GmbH & Co. KG, managed by Maguar Capital, a leading B2B software investor in the DACH region, yesterday closed on the sale of its portfolio company HRworks Holding GmbH to a newly established continuation fund, Maguar Continuation Fund I GmbH & Co. KG (“Maguar CF I”).

Zamana, recipient of the 2023 Prince’s Trust International Amal Clooney Women’s Empowerment Award Visit’s our London Office

We had the privilege of holding a breakfast with Zamana, the recipient of the 2023 Princes Trust International Amal Clooney Women’s Empowerment Award at the Asante London Office.

Private Equity’s First-Quarter Fundraising Dollars Hold Steady but Closings Fall

Fraser van Rensburg, one of Asante’s managing partners, was quoted in The Wall Street Journal for an article by Chris Cumming about Q1 2023 private equity fundraising activity.
Back to top
© Asante 2023
Design by Firedog